This study is testing a medicine called **emicizumab** in adults with **Acquired Hemophilia A (AHA)**, a condition where the blood doesn't clot properly. The study is **open-label**, meaning both doctors and patients know what treatment is given. It's a **phase II study**, which means the medicine has shown promise in earlier tests and is now being studied further. Patients will get emicizumab shots under the skin once a week after two initial doses. The medicine aims to prevent bleeding episodes over a **12-week period**. If patients aren't better, they might continue treatment for another 12 weeks. During the study, other medications to lower the immune response can be used if the doctor thinks it's needed. **Key Points:** - **Length of Study:** Initial 12 weeks, may extend to 24 weeks. - **Visits and Treatment:** Weekly subcutaneous injections. - **Eligibility:** Must be 18 or older, diagnosed with AHA, and willing to follow the study plan. Patients should not join if they have congenital hemophilia, certain infections, or are pregnant. Always discuss with your doctor to see if participating is a good choice for you.